Available Until 4/23/2024

Oncology Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT EXAM (Cert # L239065)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 04/12/2023
Content Release Date: 04/26/2023
Expiration Date: 04/23/2024
Activity Type: Application-based/Knowledge-based
CE Credits: 26.25 (BPS and ACPE) contact hours
Activity Fee: $475 (ASHP member); $675 (non-member)

These activities were recorded during a live educational event on March 2-4, 2023, at the ACCP/ASHP’s 2023 Live Review & Recertification Courses, Dallas, Texas. Learners who claimed ACPE credit for the live activities should not claim credit for these home study activities.

Activity Overview

This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study  

This online course consists of 20 activities (see table below) and provides up to 26.25 contact hours of continuing pharmacy education credit and/or recertification credit.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

  

    

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in oncology pharmacy.

Board certified pharmacists are eligible to receive up to 26.25 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment. 

This course is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/onc-review 

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS. 

Learning Activity

ACPE Number

Contact Hours

Breast Cancer

0204-9999-23-900-H01-P

2.5 ACPE

Gynecologic Malignancies

0204-9999-23-901-H01-P

1.0 ACPE

Prostate Cancer

0204-9999-23-904-H01-P

1.25 ACPE

Pediatric Malignancies and Supportive Care

0204-9999-23-917-H01-P

1.25 ACPE

  →   Recertification Assessment: Group 1 (78% passing score required)

6.0 BPS

Upper Gastrointestinal and Hepatocellular Carcinomas

0204-9999-23-905-H01-P

0.75 ACPE

Bladder, Renal Cell, and Testicular Cancers

0204-9999-23-903-H01-P

1.0 ACPE

Melanoma and Non-Melanoma Skin Cancers

0204-9999-23-906-H01-P

1.0 ACPE

Research Design, Statistics, and Evaluating Oncology Literature

0204-9999-23-907-H04-P

2.0 ACPE

  →   Recertification Assessment: Group 2 (82% passing score required)

4.75 BPS

Adult Acute Leukemias and Myelodysplastic Syndromes

0204-9999-23-908-H01-P

1.5 ACPE

Lymphomas

0204-9999-23-909-H01-P

1.25 ACPE

Chronic Leukemias

0204-9999-23-910-H01-P

1.5 ACPE

Hematopoietic Stem Cell Transplantation

0204-9999-23-911-H01-P

1.25 ACPE

  →   Recertification Assessment: Group 3 (73% passing score required)

5.50 BPS

Lung Cancer

0204-9999-23-912-H01-P

1.75 ACPE

Lower Gastrointestinal and Pancreatic Cancers

0204-9999-23-913-H01-P

1.25 ACPE

Head, Neck, Adult Central Nervous System  (CNS), and Thyroid Malignancies

0204-9999-23-902-H01-P

1.0 ACPE

Cancer-related Infectious Diseases

0204-9999-23-918-H01-P

1.0 ACPE

  →   Recertification Assessment: Group 4 (77% passing score required)

5.0 BPS

Oncology Practice Management

0204-9999-23-914-H04-P

2.0 ACPE

Multiple Myeloma

0204-9999-23-915-H01-P

1.5 ACPE

Adult Sarcomas

0204-9999-23-919-H01-P

0.75 ACPE

Pharmacogenomics in Oncology

0204-9999-23-916-H01-P

0.75 ACPE

  →   Recertification Assessment: Group 5 (83% passing score required)

5.0 BPS

At the end of the presentations, the pharmacist should be able to:

Breast Cancer
ACPE #: 0204-9999-23-900-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
  • Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
  • Identify appropriate diagnostic and prognostic tests related to breast cancer.
  • Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

Gynecologic Malignancies
ACPE #: 0204-9999-23-901-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
  • Discuss short and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
  • Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention, and screening).

Prostate Cancer
ACPE #: 0204-9999-23-904-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
  • Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

Pediatric Malignancies and Supportive Care
ACPE #: 0204-9999-23-917-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
  • Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
  •  Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

Upper Gastrointestinal and Hepatocellular Carcinomas
ACPE #: 0204-9999-23-905-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
  • Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

Bladder, Renal Cell, and Testicular Cancers
ACPE #: 0204-9999-23-903-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular carcinomas.
  • Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular carcinoma and his or her caregiver.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with tyrosine kinase inhibitors and mTOR inhibitors.

Melanoma and Non-Melanoma Skin Cancers
ACPE #: 0204-9999-23-906-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
  • Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
  • Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

Research Design, Statistics, and Evaluating Oncology Literature
ACPE #: 0204-9999-23-907-H04-P

  • Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
  • Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
  • Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
  • Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

Adult Acute Leukemias and Myelodysplastic Syndromes
ACPE #: 0204-9999-23-908-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic syndrome.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic syndrome.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
  • Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in an adult based on genomic test results.

Lymphomas
ACPE #: 0204-9999-23-909-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
  • Assess the prognostic impact of relevant cancer‐related molecular biology testing.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

Chronic Leukemias
ACPE #: 0204-9999-23-910-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia.
  • Develop an appropriate plan for preventing, monitoring, and treating infusion‐related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

Hematopoietic Stem Cell Transplantation
ACPE #: 0204-9999-23-911-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HCT).
  • Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HCT conditioning regimens.
  • Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies.
  • Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with the patient undergoing HCT and his or her caregiver.

Lung Cancer
ACPE #: 0204-9999-23-912-H01-P

  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
  • Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.

Lower Gastrointestinal and Pancreatic Cancers
ACPE #: 0204-9999-23-913-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
  • Discuss short‐ and long‐term treatment goals, including post‐therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
  • Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand‐foot syndrome, hand-foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

Head, Neck, Adult Central Nervous System  (CNS), and Thyroid Malignancies
ACPE #: 0204-9999-23-902-H01-P

  • Design an appropriate patient‐specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
  • Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
  • Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.

Cancer-related Infectious Diseases
ACPE #: 0204-9999-23-918-H01-P

  • Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
  • Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

Oncology Practice Management
ACPE #: 0204-9999-23-914-H04-P

  • Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for safe handling, administration, and disposal of hazardous drugs.
  • Select quality-improvement activities that enhance the safety and effectiveness of the medication-use process in oncology patient care.
  • Explain national accreditation and federal regulatory requirements for the care of cancer patients receiving chemotherapy or other hazardous drugs.
  • Explain medication reimbursement and patient assistance programs to optimize drug availability for oncology patients.
  • Evaluate policies and procedures related to conducting research involving investigational drugs, including drug management in patients with cancer.

Multiple Myeloma
ACPE #: 0204-9999-23-915-H01-P

  • Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
  • Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases, thromboembolism, hypercalcemia of malignancy, and spinal cord compression.

Adult Sarcomas
ACPE #: 0204-9999-23-919-H01-P

  • Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
  • Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
  • Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

Pharmacogenomics in Oncology
ACPE #: 0204-9999-23-916-H01-P

  • Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
  • Apply the results from somatic and germline genetic testing into therapy recommendations based on prognostic, predictive and patient characteristics.
  • Recognize the place in therapeutic decision making for companion diagnostic testing.

Full Faculty Bios

Jessica Auten, PharmD, BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina 

John Bossaer, PharmD, BCOP
Professor
Bill Gatton College of Pharmacy at East Tennessee State University
Johnson City, Tennessee 

Ryan Bycroft, PharmD, BCOP
Clinical Pharmacy Specialist, Hematology/Oncology
University of Louisville Hospital, Brown Cancer Center
Louisville, Kentucky 

Courtney C. Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Brette Conliffe, PharmD, BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky 

Karen M. Fancher, PharmD, BCOP*
Associate Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/UPMC Passavant Hospital
Pittsburgh, Pennsylvania 

Christopher Fausel, PharmD, MHA, BCOP
Director of Pharmacy - Precision Genomics
Indian University Health
Indianapolis, Indiana 

Lauren Ice, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist
Corewell Health
Grand Rapids, Michigan 

Alexis R. Jones, PharmD, BCOP, CPP
Clinical Pharmacist, Gynecologic Oncology
University of North Carolina Medical Center
Chapel Hill, North Carolina 

Elyse A. MacDonald, PharmD, MS, BCPS
Director, Pharmacy Services, Investigational Drug Service
Stanford Health Care
Palo Alto, California 

Janelle Mann, PharmD, BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy Services
Alvin J. Siteman Cancer Center/Washington University School of Medicine in St. Louis
St. Louis, Missouri 

Colleen McCabe, Pharm.D., BCOP
Clinical Oncology Pharmacy Specialist, Sarcoma and Melanoma
Vanderbilt University Medical Center
Nashville, Tennessee 

Donald C. Moore, PharmD, BCPS, BCOP, DPLA
Pharmacy Clinical Coordinator – Hematology/Oncology
Levine Cancer Institute – Atrium Health
Charlotte, North Carolina 

Anthony J. Perissinotti, PharmD, BCOP*
Hematology Clinical Pharmacist Specialist
University of Michigan – Michigan Medicine
Ann Arbor, Michigan 

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine M. Walko, PharmD, BCOP, FCCP*
Senior Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Tampa, Florida 

Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist – Pediatric Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio 

*Content Matter Experts

Courtney Alexander, PharmD, BCOP, BCPS
Allison Bass, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Michael Buege, PharmD, BCOP
Alison Carulli, PharmD, BCOP
Soniya Chandrasekhara, PharmD, BCOP
Jill Comeau, PharmD, BCOP
Phuong Dao, PharmD, BCOP
Bryna Ewachiw, PharmD, BCOP
Bryan Fitzgerald, PharmD, BCOP
Lisa Grate, PharmD, MS, BCOP, BCPS
Hailey Hill, PharmD, BCOP
Shahrier Hossain, PharmD, BCOP
Caren Hughes, PharmD, MBA, BCOP
Mitchell Hughes, PharmD, BCOP, BCPS
Anna Jan, PharmD, BCOP
Ashley Johns, PharmD, MS, BCOP
Justin Julius, PharmD, BCOP
Leslie Lamontagne, PharmD, BCOP
Maya Leiva, PharmD, BCOP
Andrew Li, PharmD, BCOP
Bob Luschen, PharmD, BCOP
Morgan Mace, PharmD, BCOP
Claire Mach, PharmD, BCOP
Brendan Mangan, PharmD, BCOP
Stephanie Matta, BSPharm, PharmD, BCOP
Oxana Megherea, PharmD, BCOP
Katlyn Mulhall, PharmD, BCOP
Carolyn Oxencis, PharmD, BCOP
Austin Percy, PharmD, BCOP, BCPS
Candy Peskey, PharmD, BCOP, BCPS
Farah Raheem, PharmD, BCOP
Melvin Rivera, PharmD, BCOP
Glenn Roma, PharmD, PhD, BCOP
Stephanie Sanders, PharmD, BCOP, BCCCP
Fuwang Xu, PharmD, BCOP, BCGP
Barbara Yim, PharmD, BCOP
Spencer Yingling, PharmD, BCOP
Mark Zangardi, PharmD, BCOP

Susan Abeln, RPh, BCOP
Pearl Abraham, PharmD BCPS BCOP
Stephen Aiken, PharmD, BCOP
Courtney Alexander, PharmD, BCPS, BCOP
Nada Alsuhebany, PharmD, BCOP
Laura Alwan, PharmD, BCOP
Sarah Anderson, PharmD, BCOP
Allison Bass, PharmD, BCOP
Mollie Beck, PharmD, BCOP
Denae Beckman, PharmD, BCOP
Brandon Benson, PharmD, BCOP
Janet Bramell, PharmD, BCPS, BCOP
Vickie Bridges, PharmD, BCOP
Michael Buege, PharmD, BCOP
Yuliya Byakina, PharmD, BCOP
Cathy Cao, PharmD, BCOP
Alison Carulli, PharmD, BCOP
Amanda Cass, PharmD, BCPS, BCOP
Jill Cassaday, PharmD, BCPS, BCOP
Sarah Castelo, PharmD, BCOP
Soniya Chandrasekhara, PharmD, BCOP
Kevin Chen, PharmD, MS, BCOP, CPP
Jill Comeau, PharmD, BCOP
Wendy Covert, PharmD, BCOP
Jon Crowley, PharmD, BCOP
Phuong Dao, PharmD, BCOP
Travis Dash, PharmD, BCOP
Jessica Davis, PharmD, BCOP
Bryna Delman Ewachiw, PharmD, BCOP
Kelley Doherty, PharmD, BCOP, BCPS
Ekim Ekinci, PharmD, MS, BCOP
Victor Elsasser, PharmD, BCPS, BCOP
Olivia Fahey, PharmD, BCOP
Kelsey Finch, PharmD, BCOP
Alan Fisher, BS, PharmD, BCOP
Bryan Fitzgerald, PharmD, BCOP
Susan Flatebo, PharmD, BCOP
Ramiro Garza, PharmD, BCOP
Elizabeth George, BSPharm, BCOP
Muoi Gi, PharmD, BCOP
Allison Graner, PharmD, BCOP
Lisa Grate, PharmD, MS, BCOP, BCPS
Keith Hecht, BCOP
Kristi Herald, PharmD, BCPS, BCOP
Hailey Hill, PharmD, BCOP
Mikala Hillis, PharmD, BCOP
Anna Hitron, PharmD, BCOP
Shahrier Hossain, PharmD, BCOP
Caren Hughes, PharmD, BCOP, MBA
Mitchell Hughes, PharmD, BCOP
Ying Ci (Wendy) Hui, PharmD, BCOP
Paul Hutson, PharmD, BCOP
Raymond Iannuccillo, PharmD, MBA, BCPS, BCOP
Lauren Ice, PharmD, BCOP, BCPS
Anna Jan, PharmD, BCOP
Cheryl Jee, PharmD, BCOP
Ashley Johns, PharmD, MS, BCOP
Jocelyn Joseph, PharmD, BCOP
Justin Julius, PharmD, BCOP
Amy Kamien, PharmD, BCOP
Minhee Kang, PharmD, BCPS, BCOP
Melanie Kay, PharmD, BCOP, BCPS
Mijeong Kim, PharmD, PhD, BCPS, BCOP
Tiffany Knoll, PharmD, MS, BCOP
Victoria LaMonaca, PharmD, BCOP
Leslie Lamontagne, PharmD, BCOP
Jodi Lech, PharmD, BCOP
Jessica LeClair, PharmD, MBA, BCOP
Matthew Lei, PharmD, BCOP
Maya Leiva, PharmD, BCOP
Tanja Lepir, PharmD, BCOP
Whitney Lewis, PharmD, BCOP
Andrew Li, PharmD, BCOP
Barbara Li, PharmD, BCOP
Suwicha Limvorasak, PharmD, BCOP
Pohung Lin, PharmD, BCPS, BCOP
Amanda Lucky, PharmD, BCPS, BCOP
Bob Luschen, PharmD, BCOP
Mary Mably, BSPharm, BCOP
Morgan Mace, PharmD, BCOP
Claire Mach, PharmD, BCOP
Brendan Mangan, PharmD, BCOP
Amanda Manoogian, PharmD, BCPS, BCOP
Samantha Maples, PharmD, BCOP
Jessica Marini, PharmD, BCOP
Stephanie Matta, PharmD, BCOP
Lilian May, PharmD, BCPS, BCOP, RPH
Heather McCarthy, PharmD, BCOP
Kelly McElroy, PharmD, BCOP
Oxana Megherea, PharmD, BCOP
Natoya Muirhead, Pharm.D., BCOP
Katlyn Mulhall, PharmD, BCOP
Jessica Muth, PharmD, BCPS, BCOP
Laura Nice, PharmD, BCOP
Nancy M. Nix, PharmD, BCPS, BCOP
Yevgeny Okumyansky, PharmD, BCPS, BCOP
Carolyn Oxencis, PharmD, BCOP
Tejas Patel, PharmD, BCOP
Austin Percy, PharmD, BCPS, BCOP
Candy Peskey, PharmD, BCPS, PCOP
Trevor Potts, PharmD, BCOP
Justine Preedit, PharmD, BCOP
Victoria Printz, PharmD, BCPS, BCOP
Heena Rathod, PharmD, BCOP
Mohammad Rattu, PharmD, BCOP, BCPS, BCGP
Sean Reilly, BSPharm, PharmD
Amy Riedel, PharmD, APh, BCPS, BCOP
Melvin Rivera, PharmD, BCOP
Glenn Roma, PharmD, PhD, BCOP
Erika Rugay-Buchanan, PharmD, BCOP
Teresa Rushing, PharmD, BCPS, BCOP
Danielle Rustem, PharmD, BCOP
Theresa Ryan, PharmD, BCOP
Kristen Rychalsky, PharmD, BCPS, BCOP
John Patrick Sanchez, PharmD, BCOP
Stephanie Sanders, PharmD, BCOP, BCCCP
Deborah Sarama, PharmD, BCOP
Danielle Schlafer, PharmD, BCOP
Bryan Schuler, PharmD, BCOP
Ryan Schuller, PharmD, BCOP
Shreya Shah, PharmD, BCOP
Beenish Shaikh, PharmD, BCPS, BCOP
R. Briana Shamilov, PharmD, BCOP
Diana Shen, PharmD, BCOP
Samantha Shi, PharmD, BCOP
Patrick Shin, PharmD, BCPS, BCOP
Sunao Slayton, PharmD, BCOP
Christopher Smith, PharmD, BCOP
Amy Stewart, PharmD, BCOP
Lauren Trisler, PharmD, BCOP
David Turberville, PharmD, BCOP
Malgorzata Tyszka, BScPharm, BCOP
Angela Urmanski, PharmD, BCOP
Sorana G. Ursu, PharmD, BCOP
Rachel Vaught, PharmD, BCOP
Cory Vela, PharmD, BCOP
Eric Vertin, PharmD, BCPS, BCOP
Fuwang Xu, PharmD, BCOP, BCGP
Carol Yarrington, PharmD, BCOP
Barbara Yim, PharmD, BCOP
Spencer Yingling, PharmD, BCOP
Crystal Young, PharmD, BCOP
Mark Zangardi, PharmD, BCOP
Kelsey Zielke, PharmD, BCPS, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

  • Anthony J. Perissinotti: Consultant and Advisory Board Member, Servier, BeiGene, Pfizer, Sanofi Aventis; Advisory Board Member, Abbvie, Rigel Pharmaceuticals, Janssen; Research Funding, Incyte
  • Alexis Jones: Multidisciplinary Council Member, Esai
  • Colleen McCabe: Advisory Board Member, Daichi Sankyo
  • Courtney Cavalieri: Consultant, Pfizer
  • Karen M. Fancher: Consultant, BTG Specialty Pharmaceuticals; Consultant, AstraZeneca Pharmaceuticals LP, Merck & Co
  • Mitchell Hughes: Grant Recipient, Acerta Pharma
  • Justin Julius: Speaker’s Bureau, AstraZeneca, Daiichi Sankyo, Bristol Myers Squibb; Consultant, Bristol Myers Squibb
  • Maya Leiva: Speaker’s Bureau, Bristol Myers Squibb
  • Robert Luschen: Speaker’s Bureau, Astellas/SeaGen
  • Donald Moore: Advisory Board Member, Oncopeptides, Janssen

All other planners, presenters, reviewers, ASHP staff, and others with an opportunity to control content report no financial relationships relevant to this activity.

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

ASHP collaborates with ACCP on Oncology Pharmacy activities.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.